The Metastatic Biliary Tract Cancer drugs in development market research report provides comprehensive information on the therapeutics under development for Metastatic Biliary Tract Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Metastatic Biliary Tract Cancer. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Metastatic Biliary Tract Cancer and features dormant and discontinued products.
GlobalData tracks 75 drugs in development for Metastatic Biliary Tract Cancer by 61 companies/universities/institutes. The top development phase for Metastatic Biliary Tract Cancer is phase ii with 55 drugs in that stage. The Metastatic Biliary Tract Cancer pipeline has 74 drugs in development by companies and one by universities/ institutes. Some of the companies in the Metastatic Biliary Tract Cancer pipeline products market are: Akeso, Eli Lilly and Co and Bristol-Myers Squibb.
The key targets in the Metastatic Biliary Tract Cancer pipeline products market include Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1), Vascular Endothelial Growth Factor Receptor 2 (Fetal Liver Kinase 1 or Kinase Insert Domain Receptor or Protein Tyrosine Kinase Receptor flk 1 or VEGFR2 or CD309 or KDR or EC 2.7.10.1), and Cells Expressing Receptor Tyrosine Protein Kinase ERBB 2 (Metastatic Lymph Node Gene 19 Protein or Proto Oncogene Neu or Proto Oncogene C ErbB 2 or Tyrosine Kinase Type Cell Surface Receptor HER2 or p185erbB2 or HER2 or CD340 or ERBB2 or EC 2.7.10.1).
The key mechanisms of action in the Metastatic Biliary Tract Cancer pipeline product include Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) Antagonist with eight drugs in Pre-Registration. The Metastatic Biliary Tract Cancer pipeline products include 12 routes of administration with the top ROA being Intravenous and seven key molecule types in the Metastatic Biliary Tract Cancer pipeline products market including Small Molecule, and Monoclonal Antibody.
Metastatic Biliary Tract Cancer overview
Metastatic biliary tract cancer, originating from bile duct cells, spreads to distant areas like the liver, lymph nodes, or lungs. Symptoms, like jaundice and abdominal pain, manifest late. Diagnosis entails imaging scans and biopsies. Treatment focuses on palliative care to alleviate symptoms and prolong life, employing chemotherapy, targeted therapies, or immunotherapy. Prognosis remains guarded due to advanced stage upon diagnosis and limited therapeutic options, often leading to a shorter life expectancy. Clinical trials explore innovative treatments, but metastatic biliary tract cancer poses a significant challenge, emphasizing the importance of symptom management and supportive care to enhance patients’ quality of life.
For a complete picture of Metastatic Biliary Tract Cancer’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
